The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The RENAAL Study is a double-blind, placebo-controlled trial to evaluate the renal protective effects of losartan in Type 2 diabetic patients with nephropathy. The study has enrolled 1513 patients and is expected to continue for 3.5 years after the last patient has been entered. Eligible patients must have a urinary albumin:creatinine ratio of at least 300 mg/g and serum creatinine between 1.3 to 3.0 mg/dL. Eligible hypertensive or normotensive patients are randomised to receive either losartan or placebo, in addition to their existing antihypertensive therapy. Medications that block angiotensin production or action, are excluded. The primary endpoint is a composite of the time to first event of doubling of serum creatinine, end-stage renal disease, or death; secondary endpoints include cardiovascular events, progression of renal disease, and changes in proteinuria; tertiary endpoints include quality of life, healthcare resource utilisation, and amputations. Patients include Caucasians (48.6%), Blacks (15.2%), Asians (16.7%), and Hispanics (18.2%). Baseline urinary albumin:creatinine ratio and serum creatinine levels average 1867 mg/g and 1.9 mg/dL, respectively. Mean systolic and diastolic blood pressures are 153 and 82 mmHg, respectively. RENAAL will document whether blockade of the AII receptor with losartan produces clinical benefits in patients with Type 2 diabetes and nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Cited by
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationde Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Self-citationde Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750
Self-citationKeane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch, W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00885.x · Cited by 539
Self-citationBrenner, B. M., Cooper, M. E., & de Zeeuw, D. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00549-9 · Cited by 508
Self-citationHoltkamp, F. A., de Zeeuw, D., Thomas, M. C., Cooper, M. E., de Graeff, P. A., Hillege, H. J. L., Parving, H.-H., Brenner, B. M., Shahinfar, S., & Lambers Heerspink, H. J. (2011) · Kidney International · doi:10.1038/ki.2011.79 · Cited by 364
Self-citationSurrogate Markers for Cardiovascular Disease: Functional Markers
Cohn, J. N., Quyyumi, A. A., Hollenberg, N. K., & Jamerson, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000133442.99186.39 · Cited by 284
Heerspink, H. J. L., Holtkamp, F. A., Parving, H.-H., Navis, G. J., Lewis, J. B., Ritz, E., de Graeff, P. A., & de Zeeuw, D. (2012) · Kidney International · doi:10.1038/ki.2012.74 · Cited by 257
Self-citationfor the ORIENT study investigators, Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., & Makino, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2325-z · Cited by 236
“51 mmol/l) and 12 mmHg in ORIENT compared with RENAAL patients [20].”
ResultPackham, D. K., Alves, T. P., Dwyer, J. P., Atkins, R., de Zeeuw, D., Cooper, M., Shahinfar, S., Lewis, J. B., & Lambers Heerspink, H. J. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.09.017 · Cited by 205
Self-citationComparison of different measures of urinary protein excretion for prediction of renal events
Lambers Heerspink, H. J., Gansevoort, R. T., Brenner, B. M., Cooper, M. E., Parving, H. H., Shahinfar, S., & de Zeeuw, D. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010063 · Cited by 193
Self-citationRemuzzi, G., Ruggenenti, P., Perna, A., Dimitrov, B. D., de Zeeuw, D., Hille, D. A., Shahinfar, S., Carides, G. W., & Brenner, B. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000146423.71226.0c · Cited by 123
“The study design, inclusion/ exclusion criteria, and treatment protocols have been reported previously (6, 13 ).”
BackgroundMethodSelf-citationLambers Heerspink, H. J., Weldegiorgis, M., Inker, L. A., Gansevoort, R., Parving, H.-H., Dwyer, J. P., Mondal, H., Coresh, J., Greene, T., Levey, A. S., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.09.016 · Cited by 69
Self-citationDiabetes and Cardiovascular Disease Prevention in Older Adults
Cigolle, C. T., Blaum, C. S., & Halter, J. B. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.09.001 · Cited by 50
Metadata
- Authors
- Brenner, B. M., Cooper, M. E., de Zeeuw, D., Grunfeld, J.-P., Keane, W. F., Kurokawa, K., McGill, J. B., Mitch, W. E., Parving, H. H., Remuzzi, G., Ribeiro, A. B., Schluchter, M. D., Snavely, D., Zhang, Z., Simpson, R., Ramjit, D., Shahinfar, S., & RENAAL Study Investigators
- Venue
- Journal of the Renin-Angiotensin-Aldosterone System
- Publisher
- SAGE Publications
- Published
- 2000-12
- Volume
- 1
- Issue
- 4
- Pages
- 328-335
- ISSN
- 1470-3203 (ISSN-L)
- 1752-8976
- OpenAlex
- W1983269730
- Cited by
- 139
- References
- 5
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.